Edgestream Partners L.P. Has $2.05 Million Stock Position in Haemonetics Co. (NYSE:HAE)

Edgestream Partners L.P. increased its holdings in shares of Haemonetics Co. (NYSE:HAEGet Rating) by 56.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,440 shares of the medical instruments supplier’s stock after acquiring an additional 11,354 shares during the quarter. Edgestream Partners L.P.’s holdings in Haemonetics were worth $2,049,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. State of Michigan Retirement System increased its holdings in shares of Haemonetics by 1.7% during the 1st quarter. State of Michigan Retirement System now owns 12,974 shares of the medical instruments supplier’s stock worth $820,000 after acquiring an additional 218 shares during the last quarter. Walthausen & Co. LLC acquired a new position in shares of Haemonetics during the 1st quarter worth approximately $2,214,000. Schwartz Investment Counsel Inc. increased its holdings in shares of Haemonetics by 37.0% during the 1st quarter. Schwartz Investment Counsel Inc. now owns 189,000 shares of the medical instruments supplier’s stock worth $11,949,000 after acquiring an additional 51,000 shares during the last quarter. Profund Advisors LLC increased its holdings in shares of Haemonetics by 8.9% during the 1st quarter. Profund Advisors LLC now owns 5,051 shares of the medical instruments supplier’s stock worth $319,000 after acquiring an additional 414 shares during the last quarter. Finally, Boston Partners increased its holdings in shares of Haemonetics by 1.0% during the 1st quarter. Boston Partners now owns 303,525 shares of the medical instruments supplier’s stock worth $19,069,000 after acquiring an additional 2,937 shares during the last quarter. 98.51% of the stock is owned by institutional investors and hedge funds.

Haemonetics Stock Performance

NYSE:HAE opened at $84.13 on Thursday. The stock has a fifty day moving average price of $78.56 and a 200-day moving average price of $70.97. The company has a market cap of $4.26 billion, a price-to-earnings ratio of 50.68 and a beta of 0.40. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.76 and a current ratio of 2.73. Haemonetics Co. has a fifty-two week low of $43.50 and a fifty-two week high of $86.48.

Insider Activity

In other news, EVP Michelle L. Basil sold 11,448 shares of the company’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $78.36, for a total transaction of $897,065.28. Following the completion of the sale, the executive vice president now directly owns 32,635 shares in the company, valued at approximately $2,557,278.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, EVP Michelle L. Basil sold 11,448 shares of the company’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $78.36, for a total transaction of $897,065.28. Following the completion of the sale, the executive vice president now directly owns 32,635 shares in the company, valued at approximately $2,557,278.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Michelle L. Basil sold 33,798 shares of the company’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $77.89, for a total value of $2,632,526.22. Following the sale, the executive vice president now owns 35,395 shares of the company’s stock, valued at $2,756,916.55. The disclosure for this sale can be found here. In the last three months, insiders sold 45,713 shares of company stock worth $3,566,256. 1.65% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

HAE has been the topic of a number of recent analyst reports. JMP Securities boosted their target price on Haemonetics from $90.00 to $105.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 8th. Morgan Stanley boosted their price target on Haemonetics from $85.00 to $90.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 8th. Mizuho boosted their price target on Haemonetics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, November 8th. Raymond James boosted their price target on Haemonetics from $88.00 to $100.00 and gave the company an “outperform” rating in a research note on Tuesday, November 8th. Finally, TheStreet upgraded Haemonetics from a “c+” rating to a “b” rating in a research note on Monday, November 7th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Haemonetics currently has a consensus rating of “Moderate Buy” and an average price target of $96.17.

About Haemonetics

(Get Rating)

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Further Reading

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAEGet Rating).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.